Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$12.43
-2.0%
$12.70
$8.46
$19.09
$1.69B1.48718,940 shs1.61 million shs
ModivCare Inc. stock logo
MODV
ModivCare
$3.24
-10.5%
$1.77
$0.87
$32.82
$51.96M0.761.47 million shs1.15 million shs
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
$7.43
+0.1%
$7.46
$5.67
$30.60
$122.70M-0.11161,581 shs152,905 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.00%+5.32%-3.94%-19.49%+48.91%
ModivCare Inc. stock logo
MODV
ModivCare
0.00%+8.38%+277.56%+70.75%-86.48%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
0.00%-14.91%-3.72%-29.20%-70.92%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
3.3755 of 5 stars
4.52.00.00.01.53.30.6
ModivCare Inc. stock logo
MODV
ModivCare
3.4563 of 5 stars
3.12.00.04.51.10.80.6
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
3.8924 of 5 stars
3.21.00.04.22.51.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
3.00
Buy$27.89124.37% Upside
ModivCare Inc. stock logo
MODV
ModivCare
2.25
Hold$8.38158.49% Upside
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
2.33
Hold$24.00223.01% Upside

Current Analyst Ratings Breakdown

Latest MODV, CNTA, and RAPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$35.00
5/22/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $8.00
5/22/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$48.00
5/12/2025
ModivCare Inc. stock logo
MODV
ModivCare
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
5/8/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform ➝ Outperform$6.00
5/8/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
3/31/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$38.00
3/26/2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$6.85M242.34N/AN/A$3.05 per share4.08
ModivCare Inc. stock logo
MODV
ModivCare
$2.79B0.02$14.09 per share0.23($2.69) per share-1.20
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
$1.53M80.32N/AN/A$11.51 per share0.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$235.76M-$1.81N/AN/AN/AN/A-40.22%-29.95%8/12/2025 (Estimated)
ModivCare Inc. stock logo
MODV
ModivCare
-$201.28M-$16.10N/A20.25N/A-8.33%13.64%-1.19%8/6/2025 (Estimated)
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
-$129.87M-$2.40N/AN/AN/AN/A-81.47%-70.24%8/6/2025 (Estimated)

Latest MODV, CNTA, and RAPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$0.35-$0.20+$0.15-$0.20N/AN/A
5/8/2025Q1 2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
-$2.48-$0.64+$1.84-$0.08N/AN/A
3/24/2025Q4 2024
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$0.38-$0.34+$0.04-$0.84N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/AN/A
ModivCare Inc. stock logo
MODV
ModivCare
N/AN/AN/AN/AN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.28
14.37
14.37
ModivCare Inc. stock logo
MODV
ModivCare
N/A
0.80
0.80
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/A
21.11
21.11

Institutional Ownership

CompanyInstitutional Ownership
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
82.01%
ModivCare Inc. stock logo
MODV
ModivCare
N/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
99.09%

Insider Ownership

CompanyInsider Ownership
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
7.09%
ModivCare Inc. stock logo
MODV
ModivCare
15.50%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
2.36%
CompanyEmployeesShares OutstandingFree FloatOptionable
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
200133.55 million124.09 millionOptionable
ModivCare Inc. stock logo
MODV
ModivCare
23,67514.35 million12.13 millionOptionable
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
8016.54 million16.15 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Centessa Pharmaceuticals stock logo

Centessa Pharmaceuticals NASDAQ:CNTA

$12.43 -0.25 (-1.97%)
Closing price 04:00 PM Eastern
Extended Trading
$12.46 +0.03 (+0.24%)
As of 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

ModivCare stock logo

ModivCare NASDAQ:MODV

$3.24 -0.38 (-10.50%)
Closing price 04:00 PM Eastern
Extended Trading
$3.17 -0.07 (-2.16%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ModivCare Inc., a technology-enabled healthcare services company, provides a suite of integrated supportive care solutions for public and private payors and their members. The company operates through four segments: Non-Emergency Medical Transportation (NEMT), Personal Care, Remote Patient Monitoring (RPM), and Corporate and Other. The company offers risk underwriting, contact center management, network credentialing, claims management, and non-emergency medical transport management services for Medicaid or Medicare eligible members, whose limited mobility or financial resources hinder their ability to access necessary healthcare and social services. It also provides in-home personal care services, such as bathing, personal hygiene, grooming, oral care, dressing, medication reminders, meal planning, preparation and feeding, housekeeping, transportation services, prescription reminders, and assistance with dressing and ambulation services through placing non-medical personal care assistants, home health aides, and skilled nurses primarily to Medicaid patients in need of care monitoring and assistance in performing daily living activities, including senior citizens and disabled adults. In addition, the company offers remote patient monitoring solutions, including personal emergency response systems, vitals monitoring, medication management, and data-driven patient engagement solutions. It serves federal, state, and local government agencies, MCOs, commercial insurers, private individuals, and health systems. The company was formerly known as The Providence Service Corporation and changed its name to ModivCare Inc. in January 2021. ModivCare Inc. was incorporated in 1996 and is headquartered in Denver, Colorado.

Rapt Therapeutics stock logo

Rapt Therapeutics NASDAQ:RAPT

$7.43 +0.01 (+0.13%)
Closing price 04:00 PM Eastern
Extended Trading
$7.64 +0.22 (+2.89%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company